NKMAX Confirms Improvement in Stroke Patients with NK Cell Therapy... "Proven Effective in Various Brain Disorders"

NKMAX's NK cell therapy has been shown to be effective in treating stroke.

NKMAX announced on the 17th that its subsidiary, NKGen Biotech, has received approval from the Institutional Review Board (IRB) of Angeles Hospital in Mexico and is treating stroke patients with its autologous NK cell therapy (SNK01).

The patient (63 years old) suffered from right hemiplegia and speech impairment due to a stroke three years ago and began SNK01 treatment in April. After receiving a total of seven doses of 4 billion SNK01 cells every four weeks, the patient's language ability and overall energy levels significantly improved.

Stroke, a cerebrovascular disease, is a fatal condition in which blood vessels supplying blood to the brain become blocked or rupture, causing damage to the affected brain area. In particular, when brain cells are damaged by stroke, various sequelae such as hemiplegia, speech disorders, and cognitive impairments occur. Due to population aging, the number of stroke patients is increasing, making it the second leading cause of death worldwide. According to the World Health Organization (WHO), approximately 13.7 million people worldwide suffer from stroke each year, with 5.5 million deaths.

The company explained that SNK01 appears to help with sequelae such as additional cell damage and cognitive impairments caused by neuroinflammation after stroke by improving the immune environment in the brain.

Paul Y. Song, CEO of NKGen Biotech, said, “SNK01 has been observed to show excellent effects on any brain diseases such as stroke and Alzheimer's. SNK01 seems to play an immune regulatory role in the brain by removing damaged brain cells caused by stroke and controlling inflammation.”

Meanwhile, NKGen Biotech is preparing a case report on the treatment of stroke patients.

This content was produced with the assistance of AI translation services.